Sugi Predict

Sugi Predict / Compounds / SCHEMBL630153

SCHEMBL630153

SCHEMBL630153

COC(=O)C1CN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ NPC1 O15118 2/20 0.60
▸ RAB9A P51151 2/20 0.60
▸ HTT P42858 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ NPSR1 Q6W5P4 2/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ PDE4B Q07343 1/20 0.51
▸ HTR2C P28335 1/20 0.50
▸ HPGD P15428 2/20 0.48
▸ GRIN2B Q13224 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ MMP1 P03956 1/20 0.47
▸ MMP3 P08254 1/20 0.47
▸ MMP7 P09237 1/20 0.47
▸ MMP9 P14780 1/20 0.47
▸ MMP13 P45452 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6209894 0.96 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL16655140 0.94 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL29333219 0.94 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL30994844 0.94 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL16653786 0.91 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL10239911 0.90 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL376726 0.90 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL12501669 0.90 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL12501752 0.90 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL15914276 0.90 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AHTTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215030-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 — — US disclosed
EP-4499656-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2025-02-05 — — EP disclosed
CN-119183453-A STAT modulators and uses thereof 瑞克鲁迪克斯制药股份有限公司 2024-12-24 — — CN disclosed
WO-2023192960-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-10-05 — — WO disclosed
EP-3292118-A1 AMINOESTER DERIVATIVES Chiesi Farmaceutici S.p.A. (IT) 2018-03-14 — — EP disclosed
US-20180016265-A1 AMINOESTER DERIVATIVES CHIESI FARMACEUTICI S.P.A. (IT) 2018-01-18 — — US disclosed
US-20180016265-A1 AMINOESTER DERIVATIVES CHIESI FARMACEUTICI S.P.A. (IT) 2018-01-18 — — US disclosed
US-9809582-B2 Aminoester derivatives CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-07 — — US disclosed
US-9809582-B2 Aminoester derivatives CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-07 — — US disclosed
US-9809582-B2 Aminoester derivatives CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-07 — — US disclosed
WO-2013052395-A1 1,3-SUBSTITUTED AZETIDINE PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-04-11 — — WO disclosed
EP-1869011-B1 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS ABBOTT LAB (US) 2012-08-01 — — EP disclosed
EP-2420234-A1 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as PARP inhibitors for use in treating cancer Abbott Laboratories (US) 2012-02-22 — — EP disclosed
EP-2420499-A1 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as potent PARP inhibitors Abbott Laboratories (US) 2012-02-22 — — EP disclosed
EP-1603901-B1 TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS MERCK SHARP & DOHME (GB) 2008-10-15 — — EP disclosed
US-7393858-B2 Tetrahydropyran compounds as tachykinin antagonists MERCK SHARP & DOHME LTD. (GB) 2008-07-01 — — US disclosed
CN-101155797-A 1H-benzimidazole-4-carboxamide compounds substituted at the 2-position with a quaternary carbon atom are potent PARP inhibitors ABBOTT LAB (US) 2008-04-02 — — CN disclosed
EP-1869011-A2 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS ABBOTT LABORATORIES (US) 2007-12-26 — — EP disclosed
WO-2006110816-A2 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS ABBOTT LABORATORIES (US) 2006-10-19 — — WO disclosed
US-20060172999-A1 Tetrahydropyran compounds as tachykinin antagonists MERCK SHARP & DOHME LTD. (GB) 2006-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016265-A1 AMINOESTER DERIVATIVES PDE4A, PDE3A, PDE3B SMN1; SMN2 3850/4885NPC1 4366/4885RAB9A 2754/4885
US-20060172999-A1 Tetrahydropyran compounds as tachykinin antagonists NPSR1, NPY1R, OPRL1 SMN1; SMN2 4072/4885NPC1 2953/4885RAB9A 1263/4885
US-20250215030-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A SMN1; SMN2 3676/4885NPC1 2177/4885RAB9A 2889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.